Serum sex hormones and measures of benign prostatic hyperplasia

  title={Serum sex hormones and measures of benign prostatic hyperplasia},
  author={Rosebud O. Roberts and Debra J. Jacobson and Thomas Rhodes and George G. Klee and Michael M. Leiber and Steven J. Jacobsen},
  journal={The Prostate},
Despite biologic plausibility, the associations between sex hormones and measures of benign prostatic hyperplasia (BPH) have not been consistently reported. 
Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia
This study investigates associations between polymorphisms in genes involved in sex hormone metabolism and measures of benign prostatic hyperplasia (BPH).
Benign prostatic hyperplasia – what do we know?
To present historical and contemporary hypotheses on the pathogenesis of benign prostatic hyperplasia (BPH), and the potential implications for current medical therapies.
Epidemiology and Pathophysiology of LUTS/BPO
The prevalence of benign prostatic hyperplasia is strongly related to age, ranging from 8% in men in their 50s to roughly 90 % in men older than 80 years, and chronic progressive disease, obesity, and metabolic syndrome have been recently shown to be associated with an increased risk of BPH.
Serum sex hormones and the 20‐year risk of lower urinary tract symptoms in community‐dwelling older men
Study Type – Prognosis (inception cohort)’s level of evidence’2b; level of Evidence (level of evidence)‚2a; and ‚Level of Evidence 2b.
Serum Testosterone Levels Are Negatively Correlated with International Prostate Symptom Score and Transitional Prostate Volume
To investigate the correlation of serum total testosterone levels with International Prostate Symptom Score and prostate volume in aging men, a large number of studies have found that testosterone levels in men over the age of 40 are higher than in younger men.
Is the presence of varicocele associated with static and dynamic components of benign prostatic hyperplasia/lower urinary tract symptoms in elderly men?
To evaluate the relationship between varicocele and benign prostatic hyperplasia/lower urinary tract symptoms in patients over the age of 40 years.
Risk factors for benign prostatic hyperplasia
This review summarizes recent findings regarding risk factors for benign prostatic hyperplasia (BPH), including new data on hormonal factors, growth factors, comorbid conditions and lifestyle, diet,
Testosterone Replacement Therapy on the Natural History of Prostate Disease
Proposed in this review are some theories as to how testosterone interacts to potentially ameliorate these conditions: lower urinary tract symptoms, benign prostatic hyperplasia, prostate cancer, and sexual function.


Estrogen in the etiopathogenesis of BPH
While the androgen‐dependence of the prostate gland has long been accepted, the participation of estrogen, mediated via the stroma in the elicitation of benign prostatic hyperplasia (BPH), has only
[Endocrine environment of benign prostatic hyperplasia--relationships of sex steroid hormone levels with age and the size of the prostate].
It is concluded that estrogens are key hormones for the induction and the development of BPH, and that patients with large prostates have more estrogens-dominant environments.
A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia
The results indicate that normal variation in circulating androgen levels does not influence development of BPH, but that variation in estrogen levels might be important.
Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls
Serum depression of serum testosterone and estradiol was noted for CaP patients compared to CC, although the differences were not statistically significant, and the development of clinically evident BPH was felt to be a biologically plausible response to an elevated T/E ratio.
Plasma steroid hormones, surgery for benign prostatic hyperplasia, and severe lower urinary tract symptoms
The authors' findings support opposing roles for DHT, reflected by its metabolite AAG, and E2 in the etiology of BPH.
Endocrine environment of benign prostatic hyperplasia: prostate size and volume are correlated with serum estrogen concentration.
The results suggest that an estrogen-dominant environment plays an important role in the development of BPH, and E2 levels and these two ratios were significantly correlated with prostate size.
Effects of age and sex hormones on transition and peripheral zone volumes of prostate and benign prostatic hyperplasia in twins.
It is demonstrated that before age 50 yr or before a prostate weight exceeds 30 g, prostate growth may be mainly from enlargement of the PZ and after age 50, the TZ and elevated T and dihydrotestosterone concentrations do not predispose men to prostate enlargement or symptoms of benign prostatic hyperplasia.
The pathogenesis of benign prostatic hyperplasia.
  • J. D. Wilson
  • Medicine, Biology
    The American journal of medicine
  • 1980